重新审视儿科脓毒症不同死亡风险分层中ICU入住后液体平衡:一项前瞻性观察队列研究的二次分析
该研究为美国13个PICU开展的多中心前瞻性观察队列(2003-2023年)的二次分析,纳入681例脓毒症休克患儿,用PERSEVERE-II生物标志物将患儿分为高死亡风险(n=91)、中等死亡风险(n=134)和低死亡风险(n=456)三层。主要终点为复杂性病程(死亡或至第7天持续≥2个器官功能障碍)。校正PERSEVERE-II死亡概率、第3天脓毒症相关急性肾损伤及CRRT使用后,第1-7天累积正液体平衡百分比(%PFB)作为时间依赖变量与复杂性病程风险独立相关;风险分层分析显示,第1-7天%PFB每增加10%,仅在高死亡风险层与复杂性病程风险增加相关(aHR 1.24,95%CI 1.08-1.43,p=0.003),且该关联并非由PERSEVERE-II生物标志物因果介导。作者认为,在限制性液体管理或早期启动降阶梯策略的随机试验中纳入此类预后富集工具,可能有助于在高风险患者中靶向应用这些干预。
要点
- 在681例儿科脓毒症休克患儿中,第1-7天累积正液体平衡百分比(%PFB)作为时间依赖变量,校正后与复杂性病程风险独立相关。
- 风险分层后,第1-7天%PFB每增加10%,仅高死亡风险层(n=91)复杂性病程风险增加(aHR 1.24,95%CI 1.08-1.43,p=0.003)。
- 中等死亡风险层(n=134)和低死亡风险层(n=456)中,第1-7天%PFB与复杂性病程的关联未达统计学显著。
- 该关联并非由PERSEVERE-II生物标志物因果介导。
- 作者认为,在限制性液体管理或早期启动降阶梯策略的随机试验中纳入PERSEVERE-II等预后富集工具,可能有助于在高风险患者中靶向应用干预。
适用人群与场景
- 美国13个PICU(2003-2023年)收治的681例脓毒症休克患儿。
- 按PERSEVERE-II生物标志物死亡概率分为高死亡风险层(n=91)、中等死亡风险层(n=134)、低死亡风险层(n=456)。
诊断标准与关键阈值
- 采用PERSEVERE-II生物标志物评估死亡概率并划分死亡风险分层。
- 复杂性病程定义为死亡或至第7天持续≥2个器官功能障碍。
- 第1-7天累积正液体平衡百分比(%PFB)为每日累积正液体平衡百分比。
研究设计与关键结果
- 研究类型为多中心前瞻性观察队列的二次分析,纳入681例脓毒症休克患儿,来自美国13个PICU(2003-2023年),无干预。
- 主要终点为复杂性病程(死亡或至第7天持续≥2个器官功能障碍)。
- 采用Cox比例风险回归模型,校正PERSEVERE-II死亡概率、第3天脓毒症相关急性肾损伤及CRRT使用后,时间依赖变量第1-7天%PFB与复杂性病程风险增加独立相关。
- 风险分层分析显示,第1-7天%PFB每增加10%,仅高死亡风险层(n=91)与复杂性病程风险增加相关(aHR 1.24,95%CI 1.08-1.43,p=0.003)。
- 中等死亡风险层(n=134)和低死亡风险层(n=456)中,第1-7天%PFB与复杂性病程的关联未达统计学显著。
- 该关联并非由PERSEVERE-II生物标志物因果介导。
证据类型、等级与局限
- 证据类型:多中心前瞻性观察队列研究的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在限制性液体管理或早期启动降阶梯策略的随机试验中纳入PERSEVERE-II等预后富集工具,可能有助于在高风险患者中靶向应用这些干预。
- 研究显示第1-7天%PFB每增加10%仅在高死亡风险层与复杂性病程风险增加相关(aHR 1.24,95%CI 1.08-1.43,p=0.003),中、低死亡风险层未达统计学显著。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Post-ICU admission cumulative positive fluid balance (PFB) is associated with increased mortality among critically ill patients. We sought to test whether this risk varied across biomarker-based risk strata upon adjusting for illness severity, presence of severe acute kidney injury (acute kidney injury), and use of continuous renal replacement therapy (CRRT) in pediatric septic shock.
DESIGN: Ongoing multicenter prospective observational cohort.
SETTING: Thirteen PICUs in the United States (2003-2023).
PATIENTS: Six hundred and eighty-one children with septic shock.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Cumulative percent PFB between days 1 and 7 (days 1-7 %PFB) was determined. Primary outcome of interest was complicated course defined as death or persistence of greater than or equal to two organ dysfunctions by day 7. Pediatric Sepsis Biomarker Risk Model (PERSEVERE)-II biomarkers were used to assign mortality probability and categorize patients into high mortality (n = 91), intermediate mortality (n = 134), and low mortality (n = 456) risk strata. Cox proportional hazard regression models with adjustment for PERSEVERE-II mortality probability, presence of sepsis-associated acute kidney injury on day 3, and use of CRRT, demonstrated that time-dependent variable days 1-7%PFB was independently associated with an increased hazard of complicated course. Risk-stratified analyses revealed that each 10% increase in days 1-7 %PFB was associated with increased hazard of complicated course only among patients with high mortality risk strata (adjusted hazard ratio 1.24 (95% CI, 1.08-1.43), p = 0.003). However, this association was not causally mediated by PERSEVERE-II biomarkers.
CONCLUSIONS: Our data demonstrate the influence of cumulative %PFB on the risk of complicated course in pediatric septic shock. Contrary to our previous report, this risk was largely driven by patients categorized as having a high mortality risk based on PERSEVERE-II biomarkers. Incorporation of such prognostic enrichment tools in randomized trials of restrictive fluid management or early initiation of de-escalation strategies may inform targeted application of such interventions among at-risk patients.
参考来源
- Atreya MR, Cvijanovich NZ, Fitzgerald JC, et al. Revisiting Post-ICU Admission Fluid Balance Across Pediatric Sepsis Mortality Risk Strata: A Secondary Analysis of a Prospective Observational Cohort Study. Crit Care Explor. 2024. PMID: 38234587. doi:10.1097/CCE.0000000000001027
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。